Publication at Faculty of Medicine in Hradec Králové |
2023
Abstract
The options for adjuvant treatment of malignant melanoma have expanded significantly in recent years. Based on the results of clinical studies, both immunotherapies represented by checkpoint inhibitors (pembrolizumab, nivolumab) and targeted therapy in patients with a mutation in the BRAF gene (dabrafenib plus trametinib) were gradually introduced into practice.
However, the question remains about which drug to choose for which patient. The following article summarizes the current results of clinical trials and reflects on some practical questions from practice.